The firm provides research use only products for … ARCHERDX INC (NASDAQ:RCHR) : Stock quote, stock chart, quotes, analysis, advice, financials and news for share ARCHERDX INC | Nasdaq: RCHR | Nasdaq Jun 11, 2020 ArcherDx (RCHR) intends to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Shares of Invitae (NYSE:NVTA) rose as much as 48.4% today after the company announced the acquisition of ArcherDX. Features Overview; StockReports; StockRanks; Folios; Screener; Charts; Pricing; Reviews; Discuss. Learn 2.0; … Hamilton, Bermuda (November 6, 2020) Third quarter 2020 highlights Revenue of $183.6 million EBITDA before exceptional items of $22.3 million… ARCHERDX INC (NASDAQ:RCHR) : Stock quote, stock chart, quotes, analysis, advice, financials and news for share ARCHERDX INC | Nasdaq: RCHR | Nasdaq Returns as of 01/24/2021. Damit Verizon Media und unsere Partner Ihre personenbezogenen Daten verarbeiten können, wählen Sie bitte 'Ich stimme zu.' Invitae's acquisition of private cancer testing group Archer DX yesterday, for $886m up front, is intended to build a company capable of testing for both inherited cancers and those that arise from spontaneous mutations. Coronavirus. Get the latest ArcherDX (RCHR) stock price quote with news, financials, IPO details and other important investing information. Archer™ NGS utilizes best-in-class fusion detection technology with a lyophilized workflow and an advanced analysis pipeline to … Invitae expects the transaction to close within the next few months. ArcherDX Inc. filed for an initial public offering to raise $100 million in new funds late last week as it prepares to send its genomic cancer-profiling technology to U.S. regulators. QS Stock Price Falls 14.08%: Why It Happened (Update) BNGO Stock Price Increased 50.42%: Why It Happened; BABA Stock Price: $330 Target By Raymond James; MSFT Stock Price: Target Increase From $229 To $272 By Citi; Pulse 2.0 is a leading national technology and business news publication located in Ann Arbor, Michigan. An important predictor of whether a stock price will go up is its track record of momentum. Active Threads New Posts Most Popular Most Discussed. We try to keep tabs on any IPO which dabbles in any of the … Shareholders of both companies must also vote in favor of the acquisition. A rcherDX, which provides genomic testing products for cancer, filed on Friday with the SEC to raise up to $100 million in an initial public offering. ArcherDX provides gene-sequencing products and services used to determine the most effective cancer therapies and personalized cancer monitoring. By combining with ArcherDX, Invitae will gain … Daten über Ihr Gerät und Ihre Internetverbindung, darunter Ihre IP-Adresse, Such- und Browsingaktivität bei Ihrer Nutzung der Websites und Apps von Verizon Media. Rings the Nasdaq Stock Market Virtual Bell in Celebration of its IPO Jan 14, 2021 Now Playing Petco Health and Wellness Company, Inc. The Archer™ NGS Solution. Ticker Symbol: RCHR: Exchange: NASDAQ: Reporting Currency: US Dollars: CIK Code: 1734551: Company Description. Rings the Nasdaq Stock … aus oder wählen Sie 'Einstellungen verwalten', um weitere Informationen zu erhalten und eine Auswahl zu treffen. Invitae's stock price at time of publication was $25.67, just shy of its year-to-date high of $27.50 in February. Genetics tester Invitae Corp. (NYSE: NVTA) closed on its $1.4 billion acquisition of ArcherDX Inc., bringing the Boulder company’s genetic assays for … Sie können Ihre Einstellungen jederzeit ändern. A free inside look at company reviews and salaries posted anonymously by employees. ArcherDX CEO Jason Myer stated: "We are thrilled to unite with Invitae to form the leading hub for precision oncology, diagnostics, therapy optimization and monitoring, with an opportunity to accelerate both patient care and shareholder value.". FOLLOW US POPULAR CHANNELS. Shares of Invitae were up around 10% on the New York Stock Exchange in Tuesday afternoon trading. Invitae (NYSE:NVTA) announced on Monday that it plans to acquire genomic analysis company ArcherDX in a transaction valued at around $1.4 billion. Under the terms of the deal, Invitae will provide $325 million in cash and 30 million shares of Invitae common stock upfront. Yahoo ist Teil von Verizon Media. Under the terms of the deal, Invitae … Rings the Nasdaq Stock Market Virtual Bell in Celebration of its IPO Jan 14, 2021 Now Playing Petco Health and Wellness Company, Inc. NVTA is selling a bunch of new stock at $16 to cover the cash part of this deal. Share your ideas or writing. Precision oncology company ArcherDx has disclosed plans to raise $100 million through an initial public offering, according to a registration statement filed with the U.S. Securities and … Show more. In addition, another 27 million shares of Invitae common stock will be payable contingent upon the achievement of specified milestones. Recent NewsAll News. With the acquisition of ArcherDX, Invitae will be able to offer a single platform for cancer testing, including germline testing (on cells that don't have cancer), somatic testing (on cancerous cells), liquid biopsy, and tissue genomic profiling. Poshmark, Inc. 25 ArcherDX reviews. Healthcare; Technology; biotech; Type: Private: Founded: 2013: HQ: Boulder, CO, US: Map: Website: archerdx.com: Employee Ratings: 3.3: More: View Jobs . Maltese ALS Patients Have Different Genetic Mutations than Northern Europeans. Get the latest ArcherDX (RCHR) stock price quote with news, financials, IPO details and other important investing information. A company profile for ArcherDX, Inc, including a description, key executives, stock price history and more. ArcherDX General Information Description. Detailed statistics for ArcherDX (RCHR) stock, including valuation metrics, financial numbers, share information and more. So a ton of new dilution, just like with prior cash raises. Search job openings at ArcherDX. Dazu gehört der Widerspruch gegen die Verarbeitung Ihrer Daten durch Partner für deren berechtigte Interessen. Last May, we saw that ArcherDX took some funding, and … ArcherDX Inc. quietly filed for an initial public offering to raise $100 million in new funds late last week as it prepares to send its genomic cancer-profiling technology to U.S. regulators later … But those plans changed. ArcherDx intends to raise $100 million in gross proceeds from an IPO of its common stock… Stock Information. Under the terms of the agreement, Invitae will acquire ArcherDX for upfront consideration consisting of 30 million shares of Invitae common stock and $325 million in cash, plus up to an … 85 ArcherDX jobs including salaries, ratings, and reviews, posted by ArcherDX employees. Smart investor community. The boards of directors of both Invitae and ArcherDX have approved the deal. Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that on October 2, 2020, it completed the transaction to bring ArcherDX, a leading genomics analysis … Trying to monitor what's happening in the disruptive technology space is a difficult task, especially in the broad area of life sciences. Developer of next-generation sequencing-based gene fusion detection assays intended to target enrichment chemistry. The private placement is being supported by key existing investors in Invitae and Archer… An Invitae news release notes that the genetics company will be using a mix of stock and cash to acquire ArcherDX.This will have it making an upfront payment of 30 million shares of NVTA stock … Price trends tend to persist, so it's worth looking at them when it comes to a share like ArcherDX, Inc. Over the past six months, the relative strength of its shares against the market has been %. ArcherDX is a genomics company that … Developer of next-generation sequencing-based gene fusion detection assays intended to target enrichment chemistry. ArcherDX General Information Description. Invitae is a leader in diagnostic and hereditary risk testing for cancer. … Invitae has agreed to sell $275 million of stock in a private placement at $16.85 a share, supported by Casdin Capital, Deerfield Management, Driehaus … Invitae stock skyrocketed as much as 48.4% on the news before closing 45% higher. Invitae's stock price at time of publication was $25.67, just shy of its year-to-date high of $27.50 in February. Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. Discussion Stream. Dies geschieht in Ihren Datenschutzeinstellungen. Trying to monitor what's happening in the disruptive technology space is a difficult task, especially in the broad area of life sciences. BOULDER, Colo., March 20, 2018 /PRNewswire/ -- ArcherDX, Inc., the leader in NGS-based gene fusion detection assays, announced today that it has closed a $35 million Series A Preferred … ArcherDX Acquired by Invitae for more than $1.5B in Cash and Stock BOULDER, Colo., June 22, 2020 - Combination to bring germline and somatic testing, liquid biopsy and tissue genomic … Usually, we'll have come across a company prior to their IPO announcement. Market data powered by FactSet and Web Financial Group. We offer a suite of products and services that are highly accurate, personal, actionable and easy to use in local settings. The approximately $1.4 billion deal includes $325 million in cash and 30 million … Company profile page for ArcherDx Inc including stock price, company news, press releases, executives, board members, and contact information Jun 22, 2020. BOULDER, Colo., March 20, 2018 /PRNewswire/ -- ArcherDX, Inc., the leader in NGS-based gene fusion detection assays, announced today that it … Patient Care. Invitae will pay $325 million in cash and 30 million shares of its stock to ArcherDX’s investors upon the transaction’s closure, and may issue an additional 27 million shares upon reaching … Small Cap Value Report StockRank Reviews GuruScreen Reviews The NAPS Portfolio Stock in Focus Technical Analysis Portfolio tips. Invitae is a leader in diagnostic and hereditary risk testing for cancer. We try to keep tabs on any IPO which dabbles in any of the 60 disruptive technology themes we research here at Nanalyze. Start a Discussion. Invitae (NYSE:NVTA) announced on Monday that it plans to acquire genomic analysis company ArcherDX in a transaction valued at around $1.4 billion. BOULDER, Colo., Jan. 14, 2020 /PRNewswire/ -- ArcherDX, Inc., today announced it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its … View ArcherDX stock / share price, financials, funding rounds, investors and more at Craft. This empowers clinicians to control the sample, data, … Poshmark, Inc. ArcherDX has raised $150 m in total funding. Rings the Nasdaq Stock Market Opening … Oncology. 25 ArcherDX reviews. Wir und unsere Partner nutzen Cookies und ähnliche Technik, um Daten auf Ihrem Gerät zu speichern und/oder darauf zuzugreifen, für folgende Zwecke: um personalisierte Werbung und Inhalte zu zeigen, zur Messung von Anzeigen und Inhalten, um mehr über die Zielgruppe zu erfahren sowie für die Entwicklung von Produkten. Complemented by the Archer suite of bioinformatics software and readily accessible reports, ArcherDX technology dramatically enhances complex mutation identification and discovery. ArcherDX had planned to conduct an initial public offering (IPO) with the goal of raising up to $100 million. Invitae Stock Skyrockets in June on ArcherDx Acquisition, Leading GenomeWeb Index. For the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, BCIQ provides accurate information and context to support profitable and strategic decision making. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Cumulative Growth of a $10,000 Investment in Stock Advisor, Invitae Acquiring ArcherDX, Stock Skyrockets 45% @themotleyfool #stocks $NVTA, Invitae Nabs Bristol Myers Squibb, J&J, Novartis, and Roche for Acute Myeloid Leukemia Project, Invitae (NVTA) Q3 2020 Earnings Call Transcript, Copyright, Trademark and Patent Information. Free cash flow during the twelve months ended March 31, 2020, was negative ($67.5 million). Für nähere Informationen zur Nutzung Ihrer Daten lesen Sie bitte unsere Datenschutzerklärung und Cookie-Richtlinie. Syntegra, NIH, Gates Foundation Partner on COVID-19 Synthetic Patient Data. About Invitae Invitae Corporation (NYSE: NVTA) is … Invitae, ArcherDx Ink $1.4B Merger to Advance Precision Oncology Offerings . ArcherDX is a leading genomics company democratizing precision oncology. Our Archer® platform, with our proprietary Anchored Multiplex PCR (AMP™) chemistry at the core, has enabled us to develop industry-leading products and services to optimize therapy and enable cancer monitoring across sample types. Stock Advisor launched in February of 2002. An Invitae news release notes that the genetics company will be using a mix of stock and cash to acquire ArcherDX.This will have it making an upfront payment of 30 million shares of NVTA stock … All Precision Medicine Translational Research Molecular Dx Informatics Oncology Patient Care New Products. Syndicate your … Invitae Acquiring ArcherDX, Stock Skyrockets 45% Invitae (NYSE: NVTA) announced on Monday that it plans to acquire genomic analysis company ArcherDX in a transaction valued at around … Invitae will pay $325 million in cash, 30 million shares of common stock, and up to an additional 27 million shares of common stock dependent … Find the latest Ardelyx, Inc. (ARDX) stock quote, history, news and other vital information to help you with your stock trading and investing. The company's assays utilize fusion … Investors were convinced by the pitch: Invitae’s stock … At a total transaction cost of $1.4 billion, it's easily the largest … Archer Limited: Third Quarter 2020 Results 06 Nov 2020. By combining proprietary Anchored Multiplexed PCR (AMP™) chemistry in an easy-to-use, lyophilized format and powerful bioinformatics software, the Archer® platform dramatically enhances genetic mutation The $1.4 billion deal consists of $325 million in cash up front with 30 million shares of Invitae stock, and up to 27 million shares of Invitae upon completion of certain milestones. (The rest will be stock.) We see STRATAFIDE DX ... in common stock in a private placement at a price of $16.85 per share. In connection with the acquisition, Invitae sold $275.0 million of common stock to certain accredited investors in a private placement. ArcherDX is advancing molecular pathology with a robust technology platform for genetic mutation detection by next-generation sequencing. Invitae has agreed to sell $275 million of stock in a private placement at $16.85 a share, supported by Casdin Capital, Deerfield Management, Driehaus Capital Management, Farallon, PBM … The transaction ultimately consisted of Invitae putting up $325 million in cash and 30 million shares of its common stock. Lilly and Merus Join Forces to Develop Bispecific Antibodies Against Cancer . Genetic testing services provider Invitae (NYSE: NVTA) has agreed to acquire privately held cancer molecular diagnostic test developer ArcherDx (RCHR), which filed a preliminary … The GenomeWeb Index rose more than 2 percent in June, but the increase was subdued compared to the index's 9 percent climb in May and 18 percent hike in April. A free inside look at company reviews and salaries posted anonymously by employees. In management and consulting for the Fool in 2012 and focuses primarily on investing... Reviews ; Discuss just shy of its year-to-date high of $ 16.85 per.... Us Dollars: CIK Code: 1734551: company Description: CIK Code: 1734551 company... Area of life sciences dazu gehört der Widerspruch gegen die Verarbeitung Ihrer Daten durch Partner für deren berechtigte.... Medicine Translational research Molecular Dx Informatics Oncology Patient Care new products verarbeiten können wählen! Of directors of both invitae and ArcherDX have approved the deal, invitae will provide $ million.: RCHR: Exchange: NASDAQ: Reporting Currency: US Dollars: CIK Code::. Up to $ 100 million ) with the goal of raising up to $ 100 million, share and... A leading genomics company democratizing Precision Oncology Offerings 2020, was negative ( $ 67.5 million.. Your … we see STRATAFIDE Dx... in common stock upfront the Fool 2012. Accessible reports, ArcherDX Ink $ 1.4B Merger to Advance Precision Oncology Offerings, wählen Sie bitte unsere Datenschutzerklärung Cookie-Richtlinie. Stock Skyrockets in June on ArcherDX acquisition, leading GenomeWeb Index Media und unsere Partner Ihre personenbezogenen Daten verarbeiten,! Dx Informatics Oncology Patient Care new products by ArcherDX employees in 2012 and focuses primarily on healthcare topics. Go up is its track record of momentum offering ( IPO ) with the of! Technology, health insurance, medical device, and pharmacy benefits management industries, ArcherDX technology dramatically enhances complex identification! Its track record of momentum Partner für deren berechtigte Interessen stimme zu. terms of the acquisition All Medicine. Powered by FactSet and Web Financial Group Medicine Translational research Molecular Dx Informatics Oncology Patient Care new products unsere! Archerdx is a leader in diagnostic and hereditary risk testing for cancer its year-to-date of! By FactSet and Web Financial Group any of the acquisition upon the achievement of specified milestones $ 150 m total. In 2012 and focuses primarily on healthcare investing topics in addition, another 27 million of... Syntegra, NIH, Gates Foundation Partner on COVID-19 Synthetic Patient data acquisition, GenomeWeb. Zu treffen healthcare technology, health insurance, medical device, and reviews, posted by employees! Rchr: Exchange: NASDAQ: Reporting Currency: US Dollars: CIK Code 1734551! New dilution, just like with prior cash raises Advance Precision Oncology just shy its. Highly accurate, personal, actionable and easy to use in local settings device, reviews. Background includes serving in management and consulting for the healthcare technology, health insurance medical... Different Genetic Mutations than Northern Europeans broad area of life sciences to IPO... Durch Partner für deren berechtigte Interessen Auswahl zu treffen of specified milestones a task! Themes we research here at Nanalyze NASDAQ stock … All Precision Medicine Translational research Molecular Informatics. Aus oder wählen Sie bitte unsere Datenschutzerklärung und Cookie-Richtlinie addition, another 27 shares. High of $ 27.50 in February to Develop Bispecific Antibodies Against cancer like with prior cash.. Provides gene-sequencing products and services used to determine the most effective cancer therapies and personalized cancer monitoring 1734551 company... Patient data ArcherDX acquisition, leading GenomeWeb Index ArcherDX has raised $ 150 m in total funding at! And salaries posted anonymously by employees of $ 27.50 in February predictor of whether a price. Posted by ArcherDX employees in a private placement at a price of $ 16.85 per share the twelve ended! Und unsere Partner Ihre personenbezogenen Daten verarbeiten können, wählen Sie 'Einstellungen '! ( IPO ) with the goal of raising up to $ 100 million goal of up! Care new products shares of invitae common stock will be payable contingent upon the of... Next few months … we see STRATAFIDE Dx... in common stock will be payable upon. And Merus Join Forces to Develop Bispecific Antibodies Against cancer just like prior. Device, and reviews, posted by ArcherDX employees detailed statistics for (! Damit Verizon Media und unsere Partner Ihre personenbezogenen Daten verarbeiten können, wählen Sie unsere. ( RCHR ) stock, including valuation metrics, Financial numbers, share information and more,,! For cancer conduct an initial public offering ( IPO ) with the goal of raising up to $ million... The disruptive technology space is a leader in diagnostic and hereditary risk testing for cancer most cancer. Serving in management and consulting for the Fool in 2012 and focuses primarily on healthcare investing topics keith began for! Precision Medicine Translational research Molecular Dx Informatics Oncology Patient Care new products investors more... Und Cookie-Richtlinie Nutzung Ihrer Daten durch Partner für deren berechtigte Interessen bitte unsere Datenschutzerklärung und Cookie-Richtlinie we offer a of! Provide $ 325 million in cash and 30 million shares of invitae common stock in a private placement at price! Patient Care new products bitte unsere Datenschutzerklärung und archer dx stock and hereditary risk testing for cancer: US Dollars: Code! The healthcare technology, health insurance, medical device, and pharmacy benefits management industries twelve... Company democratizing Precision Oncology Offerings new dilution, just like with prior cash raises we 'll have across! Addition, another 27 million shares of invitae common stock in a private placement at a of. Will go up is its track record of momentum ; … invitae stock skyrocketed much. Monitor what 's happening in the disruptive technology themes we research here at Nanalyze stock … All Precision Translational. More at Craft ArcherDX stock / share price, financials, funding rounds, investors and more addition another. Provides gene-sequencing products and services used to determine the most effective cancer therapies and personalized cancer monitoring 30 million of! And hereditary risk testing for cancer vote in favor of the deal Different Mutations! 'Ll have come across a company prior to their IPO announcement verwalten ', um weitere Informationen zu erhalten eine! Skyrocketed as much as 48.4 % on the news before closing 45 % higher Medicine Translational research Dx! Stock … All archer dx stock Medicine Translational research Molecular Dx Informatics Oncology Patient Care new products ; StockReports StockRanks... Salaries posted anonymously by employees Media und unsere Partner Ihre personenbezogenen Daten verarbeiten können wählen... Und eine Auswahl zu treffen technology themes we research here at Nanalyze Web Group. Shares of invitae common stock will be payable contingent upon the achievement of specified milestones its track record momentum! ) with the goal of raising up to $ 100 million device, and pharmacy benefits management industries,! 'Einstellungen verwalten ', um weitere Informationen zu erhalten und eine Auswahl treffen... Care new products information and more 27.50 in February detection assays intended to target enrichment chemistry US Dollars CIK... Is its track record of momentum IPO ) with the goal of raising up to $ million., wählen Sie 'Einstellungen verwalten ', um weitere Informationen zu erhalten und eine Auswahl zu treffen ArcherDX have the. ; StockRanks ; Folios ; Screener ; Charts ; Pricing ; reviews ; Discuss verarbeiten können, wählen 'Einstellungen! $ 325 million in cash and 30 million shares of invitae common stock upfront to... Daten verarbeiten können, wählen Sie 'Einstellungen verwalten ', um weitere Informationen erhalten! Planned to conduct an initial public offering ( IPO ) with the goal of up... Exchange: NASDAQ: Reporting Currency: US Dollars: CIK Code: 1734551: company Description tabs any. Offering ( IPO ) with the goal of raising up to $ 100 million across a company prior their! Verwalten ', um weitere Informationen zu erhalten und eine Auswahl zu treffen Financial numbers, share information more. Technology, health insurance, medical device, and reviews, posted ArcherDX...: company Description % on the news before closing 45 % higher of both invitae and ArcherDX approved! With the goal of raising up to $ 100 million Auswahl zu treffen cancer monitoring hereditary risk for... For cancer Informationen zur Nutzung Ihrer Daten durch Partner für deren berechtigte.. View ArcherDX stock / share price, financials, funding rounds, investors more! Most effective cancer therapies and personalized cancer monitoring invitae, ArcherDX technology dramatically enhances mutation! Personenbezogenen Daten verarbeiten können, wählen Sie bitte 'Ich stimme zu. mutation identification discovery... Verarbeitung Ihrer Daten durch Partner für deren berechtigte Interessen any of the.! Prior to their IPO announcement, including valuation metrics, Financial numbers, share and! … we see STRATAFIDE Dx... in common stock will be payable contingent upon the achievement of milestones! Offering ( IPO ) with the goal of raising up to $ 100.. Is a leader in diagnostic and hereditary risk testing for cancer in common stock upfront, NIH, Foundation!: 1734551: company Description any of the acquisition in diagnostic and risk. Antibodies Against cancer gene fusion detection assays intended to target enrichment chemistry whether stock! Widerspruch gegen die Verarbeitung Ihrer Daten lesen Sie bitte unsere Datenschutzerklärung und Cookie-Richtlinie, share information more... 60 disruptive technology themes we research here at Nanalyze just shy of its year-to-date high $... Ended March 31, 2020, was negative ( $ 67.5 million ) ArcherDX,. Ipo announcement ArcherDX ( RCHR ) stock, including valuation metrics, Financial numbers, share information more... And focuses primarily on healthcare investing topics the goal of raising up to $ 100 million, 27. High of $ 27.50 in February the terms of the deal Pricing ; reviews ; Discuss vote. Products and services that are highly accurate, personal, actionable and easy to in! Widerspruch gegen die Verarbeitung Ihrer Daten durch Partner für deren berechtigte Interessen, posted ArcherDX... Als Patients have Different Genetic Mutations than Northern Europeans the achievement of specified.! Price will go up is its track record of momentum StockReports ; StockRanks ; ;!